2007
Taxane-Based Chemotherapy for Prostate Cancer
Mohile S, Petrylak D. Taxane-Based Chemotherapy for Prostate Cancer. Contemporary Cancer Research 2007, 445-462. DOI: 10.1007/978-1-59745-224-3_23.Peer-Reviewed Original ResearchHormone-refractory prostate cancerTreatment of HRPCProstate cancerProgressive hormone-refractory prostate cancerCastrate testosterone levelsTaxane-based chemotherapyTaxane-based therapyProgression of diseaseTAX 327Adjuvant treatmentMetastatic diseaseSurvival benefitClinical outcomesDisease complicationsDismal prognosisSignificant morbidityAvailable therapiesEndothelin receptorsTargeted therapyTestosterone levelsTreatment liesChemotherapeutic agentsDrug resistanceTherapyMinimal toxicity
2006
Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC)
Petrylak D, Mohile S, Shelton G, Carr R, Steinberg J, Sleep D, Melia J, Rieser M, Nanus D, Milowsky M. Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC). Journal Of Clinical Oncology 2006, 24: 14512-14512. DOI: 10.1200/jco.2006.24.18_suppl.14512.Peer-Reviewed Original ResearchHormone-refractory prostate cancerPSA declineAdverse eventsTreatment of HRPCPhase III clinical developmentPhase III studyRefractory prostate cancerUnexpected adverse eventsDOC infusionNeutropenic feverIII studyLiver metastasesOral dosesPO QDSelective endothelinPK interactionsReceptor antagonistPlasma concentrationsProstate cancerCYP3A4 activityClinical developmentDay 1DocetaxelPK resultsPharmacokinetics